Physician profile
Roberto R Ramirez
NPI 1295761013
$843.35
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.03 · 2020: $111 · 2021: $148 · 2022: $46.78 · 2024: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $447.00 | 2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $126.80 | 2020-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $75.49 | 2020 | |
| Nxstage Medical, INC. | $73.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.82 | 2021 | |
| Akebia Therapeutics INC | $18.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2022 | |
| Horizon Therapeutics Plc | $17.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.56 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.